Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Haegarda reduces HAE attacks by 98 percent
December 2017
SHARING OPTIONS:

KING OF PRUSSIA, Pa.—CSL Behring closed October with a presentation at the 2017 American College of Allergy, Asthma & Immunology Annual Scientific Meeting. The data showed that at the approved dose of 60 IU/kg, Haegarda reduced the median number of monthly hereditary angioedema (HAE) attacks by 98 percent in patients who had frequent attacks, from a 16-week placebo period to a 16-week treatment period. The breakthrough attack rate (extrapolated to one year) was reduced from roughly 70 attacks per year for patients receiving placebo to roughly six attacks per year for patients receiving Haegarda. The medicine is a self-administered, subcutaneous, plasma-derived concentrate of C1-INH, injected twice weekly. Haegarda replaces the deficient or dysfunctional C1-INH protein, restoring C1-INH levels above 40 percent, which is thought to reduce the risk of attacks. It was approved by the FDA on June 22 for routine prophylaxis to prevent HAE attacks in adolescents and adults.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.